Humans have prevailed in the battle with most other species, including bacteria and viruses. The target of medical treatment has changed to systemic diseases that occur without provocation, such as cancers and degenerative diseases.
As an ophthalmologist, when I examine patients with incurable diseases, I always hope to relieve their suffering, but often have a sense of helplessness. One day, Dr. Yoshimura, a professor in the department of ophthalmology at Kyoto University, challenged me to start a bio-venture company. I founded KDDD (Kyoto Drug Discovery & Development Co., Ltd.), which remains affiliated and collaborates with Kyoto University.
KDDD develops KUSs (Kyoto University Substances). The first inventor of a product is Dr. Kakizuka, professor in the graduate school of biostudies at Kyoto University; the second inventor is Dr. Ikeda, associate professor at Kyoto University Hospital. KUSs are novel compounds that improve ATP consumption by inhibiting the ATPase of VCP and protect cells from a lot of kind of damages, such as degeneration and ischemic damage. In animal models, KUSs have neuroprotective effects for chronic degenerative diseases such as retinitis pigmentosa and glaucoma. Our mission is to develop KUSs for treatment of patients with incurable eye disease. As KUSs have a unique mechanism, they may also provide strong cell-protective effects in other diseases.
- strong passion to develop and make drugs available for incurable diseases
- strong social responsibility
- gratitude to society, academia, and the medical field
We promise a sincere commitment to global health.
Our mission is to supply effective drugs for current and future patients with incurable diseases.
Kyoto Drug Discovery & Development Co., Ltd.
International Science Innovation Building, Kyoto University
#416, Med-Pharm Collaboration Building, Kyoto University
5-52-206 Fudegasaki-cho, Tennoji, Osaka, 543-0027, JAPAN
|President & CEO||
|Major Business Activities||
Research and Development of Drug, Diagnostic Drug, Human Cell Therapy and Gene therapy Products, Medical Equipment, Medical Instruments, Reagent and Medical Supplies
May 15th. 2015
|Account Closing Month||
161.4 mi. yen（as of February 28th, 2018）
Bank of Tokyo-Mitsubishi UFJ, Toji Branch
|February 28th, 2018||
Total 142.8mil. Yen investments from two venture capitals
|August 1st, 2017||
Labo was established in a building in Kyoto University
|September 27th, 2016||
Headquarters moves into a building in Kyoto University
|June 30th, 2016||
Total 430mil. Yen investments from five venture capitals
|June 17th, 2016||
Capital reached 140mil. Yen (including capital reserve)
|March 30th, 2016||
License Agreement with Kyoto University
|May 15th, 2015||
Established (Capital 21mil. Yen)
KDDD aims to bring “Brightness” to patients with incurable diseases, now and in the future, by development of seeds discovered at Kyoto University. KDDD was conceived in the department of ophthalmology and graduate school of biostudies of Kyoto University in May 2015. KDDD, as a university-sponsored venture, will maintain a strong partnership with Kyoto University and promote development of our product.
|Representative Director, CEO||Head Administrative Officer||Kunihiro Musashi|
|Director||Research Promotion Department
|Director||CMC Planning Department
|Director||Business Development Department
|Clinical Development Department
|CMC Planning Department
Research Promotion Department
|Outside Director||Kyoto University Innovation Capital||Nobuhiro Yagi|
|Outside Company Auditor|| Kazuyoshi Tsuda CPA and
certified tax accountant office
|Medical Advisor|| Kyoto University
|Medical Advisor|| Kyoto University Hospital
|Hanako Ohashi Ikeda|
KUSs, Kyoto University Substances, are valosin-containing protein (VCP) modulators. They ameliorated abnormally low ATP levels by inhibiting the ATPase of VCP, thereby protected cells from degeneration and death. Several reports were provided that KUSs have neuroprotective effects that protect retinal nerve fibers and retinal ganglion cells on animal models. The facts may contribute to deterioration restraint of glaucoma. Glaucoma is a leading cause of vision loss worldwide. Lowering intraocular pressure by drugs and/or surgery is the only evidence-based treatment of glaucoma. We believe that KUSs will be able to provide convenient novel therapeutics for neuroprotection in incurable eye diseases such as glaucoma. KUSs may also provide novel strategy for cell protection in other areas.